Kyverna Therapeutics, Inc. — Form 10-K Summary
Business context and reporting period
Kyverna is a clinical-stage biopharmaceutical company developing autologous and allogeneic cell therapies for autoimmune diseases. Its lead candidate, KYV-101, is a fully human CD19 CAR T-cell therapy being studied in lupus nephritis, systemic sclerosis, myasthenia gravis and multiple sclerosis. KYV-201 is an allogeneic, gene-edited CD19 CAR T-cell program being developed with Intellia Therapeutics. The filing covers the year ended December 31, 2023. The company had no approved products and no product-sales revenue. Its common stock began trading on Nasdaq under “KYTX” on February 8, 2024.
Financial performance and position
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Collaboration revenue | $0.0 million | $7.0 million | Down 100% |
| Research and development expense | $49.9 million | $28.4 million | Up 76% |
| General and administrative expense | $12.5 million | $8.0 million | Up 56% |
| Operating loss | $62.4 million | $29.4 million | Loss increased $33.0 million |
| Net loss | $60.4 million | $28.9 million | Loss increased $31.5 million |
| Net loss per share | $89.61 | $63.43 | Not comparable due to pre-IPO capital structure |
| Net cash used in operating activities | $52.4 million | $36.1 million | Use increased $16.3 million |
Operating and net margins are not meaningful because the company had no product revenue and only $7.0 million of related-party collaboration revenue in 2022. Interest income increased to $2.3 million from $0.6 million, partially offsetting operating losses.
At December 31, 2023, cash and cash equivalents were $34.6 million, available-for-sale marketable securities were $22.9 million, and total cash, cash equivalents and marketable securities were $57.5 million. Total assets were $75.2 million and total liabilities were $26.0 million. Liabilities included $6.3 million of accrued related-party license expense, $7.2 million of operating lease liabilities and $1.9 million of finance lease liabilities. The filing does not identify conventional funded debt as a material financing source.
Material changes versus the prior comparable period
- Collaboration revenue fell to zero after Gilead-related research programs were completed and revenue was fully recognized in 2022. The Gilead agreement terminated effective January 22, 2024.
- Research and development expense increased primarily because of greater CRO, CMO and clinical-trial spending, additional personnel, and advancement of KYV-101 and KYV-201.
- KYV-101 external program costs increased to $18.3 million from $6.7 million, while KYV-201 costs increased to $4.5 million from $0.4 million.
- Net cash used in operations increased to $52.4 million from $36.1 million as development activities expanded.
- The company raised approximately $59.9 million, net of issuance costs, through Series B preferred stock financings during 2023.
- After year-end, the February 2024 IPO issued 16.675 million common shares at $22.00 per share and generated approximately $336.2 million of net proceeds. All preferred stock converted into 25.171 million common shares.
Clinical progress, outlook and risks
As of December 31, 2023, 14 patients had been dosed with KYV-101, including three in Kyverna-sponsored trials. Two lupus nephritis trials were enrolling, and the company received IND clearances during 2023 for planned studies in systemic sclerosis, myasthenia gravis and multiple sclerosis. Early observations in three lupus nephritis patients and other named-patient or investigator-initiated settings showed disease and biomarker improvements, with no serious CRS or ICANS reported in the first 13 autoimmune patients with 28-day follow-up. These observations are preliminary, arise from small or uncontrolled settings, and generally cannot be used to establish regulatory efficacy.
Management expects substantial increases in research and development, manufacturing, regulatory, personnel, public-company and infrastructure costs. The company expects continued operating losses and negative operating cash flow and does not expect product revenue for the foreseeable future. Management stated that year-end liquidity together with IPO proceeds was sufficient to fund the planned operating program for at least one year from the financial statement issuance date, but additional capital will likely be required.
- Clinical, regulatory and commercial success is uncertain; no product candidate has completed pivotal development or received marketing approval.
- CAR T-cell therapies carry risks including cytokine release syndrome, ICANS, infections and potential T-cell malignancies. The FDA’s investigation into T-cell malignancies following autologous CD19- or BCMA-directed CAR T therapies could lead to additional scrutiny, warnings or post-approval requirements.
- The company relies on third parties, including WuXi for KYV-101 manufacturing, Oxford Biomedica for lentiviral-vector development and ElevateBio for manufacturing-process development. Supply interruptions, regulatory deficiencies or geopolitical restrictions could delay trials.
- Kyverna depends on licensed intellectual property from the NIH, Intellia and Kite/Gilead and may owe future milestones, royalties and sublicense payments. The Kite-related accrued license expense includes $2.5 million expected to be paid by mid-2024; the payment timing for the remaining $3.8 million was unresolved.
- The company identified material weaknesses in internal control over financial reporting and concluded that disclosure controls were not effective as of December 31, 2023. Remediation is expected to extend through fiscal years 2024 and 2025.
- Clinical results from named-patient treatments and investigator-initiated trials may not be representative, may not support regulatory approval and could expose the company to additional regulatory, safety and liability risks.
- Competition includes approved immunosuppressive and biologic therapies, stem-cell transplantation and other emerging CAR T-cell and B-cell-directed programs.
Most important facts for investors to verify
- Confirm the post-IPO cash runway, quarterly cash burn and whether management’s planned operations remain consistent with the stated funding horizon.
- Track enrollment, safety, durability and objective efficacy endpoints in the sponsored KYV-101 trials, distinguishing them from uncontrolled named-patient reports.
- Assess the impact of FDA scrutiny concerning T-cell malignancies on trial design, consent requirements, labeling and approval timelines.
- Review manufacturing readiness, capacity, quality compliance and dependence on WuXi, Oxford Biomedica and ElevateBio.
- Quantify future milestone, royalty, license and accrued related-party obligations, including the unresolved Kite/Gilead payment schedule and Intellia milestones of up to $64.5 million.
- Monitor remediation of the material weaknesses and future auditor or management assessments of internal control over financial reporting.
- Evaluate dilution from the IPO, equity plans, outstanding options and potential future financing needs.